DGAP-News: CANCOM Group grows in all business segments in

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Aug 7, 2014 at 6:30 AM

DGAP-News: CANCOM Group grows in all business segments in the first half of the year

DGAP-News: CANCOM SE / Key word(s): Half Year Results CANCOM Group grows in all business segments in the first half of the year 07.08.2014 / 12:19 --------------------------------------------------------------------- CANCOM Group grows in all business segments in the first half of the year Key financial indicators continued to increase significantly in the second quarter and in the first six months Munich, August 7, 2014 - In its 2014 semiannual report, CANCOM SE confirms its successful business performance in the first half of the current year, which the preliminary figures previously announced had also shown. With their strong overall performance, both reporting segments have contributed to the growth in revenues and profit. The GroupÊ¼s consolidated sales in the second quarter compared with the previous year rose by 35.2%, from 140.0 million euros to 189.3 million euros. The expansion of higher-margin products and services is the reason for the GroupÊ¼s further improved gross profit and gross profit margin. This amounts to an increase of 33.3% for the second quarter of 2014 with a gross profit of 63.1 million euros, following the previous year which saw an increase of 32.7% and a gross profit of 45.8 million euros. Adjusted for one-off effects, Group EBITDA grew by 46.2% from 7.8 million euros to 11.4 million euros, equivalent to an adjusted EBITDA margin of 6.0% in the second quarter of the current year, compared with 5.6% in the previous year. The one-off effects of 0.1 million euros are external expenses in connection with the acquisitions, not to be capitalized pursuant to IFRS and not incurred related to the operational business. Group EBITA (earnings before interest, taxes, and amortization on intangible assets) also adjusted for one-off effects is 8.2 million euros for the second quarter, compared with 5.8 million euros in 2013, an increase of 41.4%. In total, the one-off effects together with the amortization effects from the purchase price allocation (PPA) adjusted profit amount to 0.36 euros per share for the second quarter in 2014, compared to 0.34 euros in 2013. For the first six months of the current financial year, the GroupÊ¼s consolidated sales revenues grew 36.2% to 374.7 million euros, increasing from 275.1 million in the first half of 2013. Adjusted for one-off effects amounting to 0.6 million euros in the first half of 2014, Group EBITDA increased by 48.6% to 22.0 million euros, in comparison to the previous year with 14.8 million euros, which corresponds to an adjusted EBITDA margin of 5.9% following 5.4% in 2013. The Cloud Solution segment has made a significant contribution with a 140.0% increased EBITDA of 10.8 million euros (Q2/2013: 4.5 million euros) and a segment EBITDA margin of 23.2% (Q2/2014: 21.3%). Adjusted for one-off effects, the Group EBITA margin of the first half of 2014 is at 15.9 million euros-a gain of 45.9% compared to the previous year at 10.9 million euros. For the first half of the year, profits adjusted for one-off effects and PPA amortization were achieved in the amount of 0.71 euros per share, as compared to 0.63 euros per share in 2013. With a balance-sheet equity ratio of around 50%, the CANCOM Group has a solid capital structure. Liquid assets worth 65 million euros as of June 30, 2014, allow financing of the organic and acquisitional growth of the IT group. "With a very good first half of the year, we have established a comfortable starting point for a successful 2014 with new record values," states CANCOM CEO Klaus Weinmann. "A stable macroeconomic framework and a traditionally strong fourth quarter should have an additional positive impact on the development." Contact: Beate Rosenfeld Manager Corporate Communication & IR CANCOM SE Erika-Mann-StraÃe 69 80636 MÃ¼nchen Germany Phone: +49 (0) 89 / 54054 5193 mail to: beate.rosenfeld@cancom.de www.cancom.de --------------------------------------------------------------------- 07.08.2014 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: CANCOM SE Erika-Mann-StraÃe 69 80636 MÃ¼nchen Germany Phone: +49-(0)89/54054-0 Fax: +49-(0)89/54054-5119 E-mail: info@cancom.de Internet: http://www.cancom.de ISIN: DE0005419105 WKN: 541910 Indices: TecDAX Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, DÃ¼sseldorf, Hamburg, MÃ¼nchen, Stuttgart End of News DGAP News-Service --------------------------------------------------------------------- 281273 07.08.2014

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Layne's Chicken Fingers Expands with Brownsville Opening

Fried Delights Rise in Brownsville Never thought I'd see the day when chicken fingers felt like the main character in an epic expansion saga, but here we are. Ricki Oberoi, a veteran in the fast-food game, is pushing onward with Layne's Chicken Fingers in Brownsville, Texas. I tell you, some folks are as keen on expanding their palates as they are their portfolios....

AppLovin Legal Woes: A Deep Dive into Investor Claims

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Innovent's Seven Drugs Leap onto 2026 Reimbursement Chart

A Bold Move in Biopharmaceuticals Innovent Biologics just pulled a rabbit out of their hat. Seven of their cutting-edge meds made it onto China's National Reimbursement Drug List for 2026. This isn't just a spreadsheet entry—it's a lifeline thrown to patients across the oncology, metabolic, and autoimmune landscapes, as well as a financial booster for Innovent (HKEX:...

HONGQI's EHS4 Launch in Europe: Bridging East and West

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

Greenberg Traurig's Brad Kaufman: A Mentor of Resolute Impact

A Milestone for Mentorship at Greenberg Traurig In the often cutthroat jungle of law, finding someone who actually gives a damn about you is as rare as finding a unicorn. Yet, there it is—Brad Kaufman, at the helm of Greenberg Traurig's professional development, proving that mentorship can be more than just a checkbox on a quarterly review. Award for Exceptional...

YSTUDIO's Pens: A Nod to the Power of Writing

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

EFICYENT Ventures to Connect at Singapore FinTech Fest

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Novo's CagriSema Trial Shows Promising Obesity Results

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

HiTHIUM Joins Cambridge to Boost Global Energy Storage

HiTHIUM and Cambridge's New Energy Venture There's a big splash coming out of Xiamen, folks. HiTHIUM, a heavyweight in the energy storage sector, has decided to team up with the University of Cambridge. They inked a deal aiming to bridge the academic ivory tower with industrial grit, focusing on long-duration energy storage. It was all sealed during the Global Energy...

Beko Pushes for Policy Synergy Amidst Carbon Shakeup

When big names like Beko step up on the global stage, you pay attention. During the COP31 panels in Antalya, Türkiye, the company's brass made one thing clear: we need harmony in how climate, trade, and finance policies come together. The stakes? The very strength of industrial competitiveness as new carbon rules turn the heat up on manufacturing practices. The Call for...